Skip to main content

ACR 2017

ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Read More
ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Read More
ACR 2017, Conference Correspondent
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
Read More
ACR 2017, Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Read More
ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Read More
ACR 2017, Conference Correspondent
Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA
Read More
ACR 2017, Conference Correspondent
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
Read More
ACR 2017, Conference Correspondent
Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
Read More
ACR 2017, Conference Correspondent
Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis
Read More
ACR 2017, Conference Correspondent
Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
Read More
Page 1 of 2
Results 1 - 10 of 20